June 2014- Volume 10, Issue 6

June 2014

In this Issue

Research & Development

Going global against Alzheimer’s

Going global against Alzheimer’s

World Dementia Council sets strategies to reach the goal of treatment by 2025

Serum stable

Serum stable

Novozymes Biopharma will offer a drug-albumin conjugation platform in collaboration with ThioLogics

Getting more ‘MIF’ed

Getting more ‘MIF’ed

Debiopharm and Yale broaden collaboration on MIF inhibitors for autoimmune and inflammatory diseases

New biochip mimics liver

New biochip mimics liver

Technology promises simplified toxicity testing of drug candidates

Discovery

A natural fit for natural products?

A natural fit for natural products?

California’s ChromaDex pairs with Brazil’s LNBio for joint research agreement

Playbook for a pathogen

Playbook for a pathogen

Researchers sequence H99 strain of Cryptococcus neoformans, a potentially deadly human pathogen

Calibr receives Gates Foundation grant

Calibr receives Gates Foundation grant

Goal is to lead collaborations to develop an Integrated Drug Discovery Platform for diseases of the developing world

Scripps launches new drug discovery initiative

Scripps launches new drug discovery initiative

Aim is to translate early-stage biomedical research into clinical candidates

Clinical Trials

Shire to acquire Lumena in pipeline expansion

Shire to acquire Lumena in pipeline expansion

Acquisition strengthens Irish company’s rare disease pipeline and profitable GI business

Going for leadership in cellular therapy

Going for leadership in cellular therapy

NeoStem acquires California Stem Cell and moves forward with Phase 3 trial for melanoma

Aegerion looks to bring lomitapide to Japan

Aegerion looks to bring lomitapide to Japan

Phase 3 trial focuses on treatment of homozygous familial hypercholesterolemia

Hope for prostate cancer and BPH

Hope for prostate cancer and BPH

Nymox reports that prostate cancer treatment does not affect testosterone levels

Taking a swipe at resistant infections

Taking a swipe at resistant infections

Cubist moves treatment for antibiotic-resistant infections beyond Phase 3

Diagnostics

Idera and Abbott seek new companion

Idera and Abbott seek new companion

Abbott will develop a companion diagnostic for Idera’s IMO-8400 for use in genetically defined forms of B-cell lymphoma

Going international

Going international

Foundation Medicine announces key developments in international commercialization efforts

Curtailing a ‘diagnostic odyssey’

Curtailing a ‘diagnostic odyssey’

Indi’s Series B round will help commercialize Xpresys Lung, a diagnostic for identifying benign lung nodules

On point

On point

DNA Electronics secures funding to develop Genalysis point-of-care genomic diagnostics product line

Preclinical

Facing down Factor VIII intolerance

Facing down Factor VIII intolerance

Apitope moves potential hemophilia A peptide therapy into preclinical development

See how they run

See how they run

Mice with MS-like virus recover after human stem cell injections, offering hope for human cure

New antiviral drug targets measles outbreaks

New antiviral drug targets measles outbreaks

If it works in humans, it could protect infected people from getting sick and keep them from spreading the virus

Disease-modifying treatment for COPD

Disease-modifying treatment for COPD

Domainex program shows promise for treatment of not just COPD but possibly other inflammatory diseases

Business & Government Policy

Valeant vies for Allergan

Valeant vies for Allergan

In light of Allergan’s rejection of its merger proposal, Valeant ups the ante

Takeda, Eli Lilly found liable by jury in Actos claims

Takeda, Eli Lilly found liable by jury in Actos claims

Verdict calls upon the companies to pay $9 billion in damages over bladder cancer possibly related to Actos use

GSK, Novartis ink transformational agreement

GSK, Novartis ink transformational agreement

Transaction expected to result in a leading OTC business with $10 billion in sales

Allergy shot alternative

Allergy shot alternative

Two new sublingual drugs combat common allergies

Pfizer loses bid for AstraZeneca

Pfizer loses bid for AstraZeneca

Final offer of $117 billion insufficient to allay concerns about Pfizer’s plans and woo AstraZeneca to negotiating table

Special Reports

Special Report: Cancer in the clinic - Are we all fighting for the same endgame?

Special Report: Cancer in the clinic - Are we all fighting for the same endgame?

A little over a year ago, we published a special report on the challenges facing new oncology drugs as they moved through the clinical trial process. This time, Randall C Willis looks further into this challenge by examining the clinical trial process itself

Q&A

Carbohydrate-based answers for diabetes, hypoxic tissue and cell death

Carbohydrate-based answers for diabetes, hypoxic tissue and cell death

DDNews spends some time talking to Dr. David Platt of Boston Therapeutics Inc. about carbohydrate chemistry and his company's work, and what it all means to some key areas of concern in drug discovery and healthcare

Editor's Focus

The word on ‘The Street’ is: Shopping

The word on ‘The Street’ is: Shopping

DDNews' chief editor muses on merger and acquisition trends in pharma and biotech and some films about Wall Street, and ponders whether the big-money M&As are worth it overall (for the industry and the patients)

Commentary

Red tape rising

Red tape rising

We’ve reached the stage where the pursuit of funding is overtaking the pursuit of doing science, says columnist Peter T. Kissinger, and that isn't good for anyone, nor is the idea of envisioning a world where everyone who wants grants gets them

Guest commentary: The clinical trial landscape and its data collection challenges

Guest commentary: The clinical trial landscape and its data collection challenges

Clinical trials are one of the most important components of the drug development process, but they are also one of the most costly, and much of that expense (both money and time) is due to data collection
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 4 • April 2021

April 2021

April 2021 issue